Nintedanib could potentially lead to improvements in anti-melanoma differentiation-associated 5 dermatomyositis-associated interstitial lung disease

CONCLUSIONS: Nintedanib may be effective for improving clinical symptoms, laboratory parameters, lung lesions, and survival in anti-MDA5+ DM. Diarrhoea was the most common adverse event associated with nintedanib, although the drug was well tolerated by most patients.PMID:38153137 | DOI:10.55563/clinexprheumatol/c0i032

Source: Clinical and Experimental Rheumatology - December 28, 2023 Category: Rheumatology Authors: Xixia Chen Wei Jiang Qiwen Jin Sang Lin Lu Zhang Qinglin Peng Hongliang Sun Yuli Wang Xin Lu Aiping Song Guochun Wang Yongpeng Ge Source Type: research